In this study, to determine whether SIRT7 can be used as a prognostic biomarker, we compared the expression levels of SIRT7 association with prognosis in different breast cancer subtypes (luminal A, luminal B, HER2+, and basal) using Kaplan-Meier survival curves. This evidence concerns the gene ERBB2 and breast carcinoma.